Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEmv Capital Regulatory News (EMVC)

Share Price Information for Emv Capital (EMVC)

Share Price is delayed by 15 minutes
Get Live Data
49.00    0.00 (0.00%)
Bid:
48.00
Ask:
50.00
Spread: 2.00 (4.167%)
Market Cap: £13.70m
EMVC Live PriceLast checked at - London Stock Exchange

Intraday Emv Capital Share Chart

Sofant Technologies: Fundraising

23 Dec 2025 07:00

RNS Number : 5619M
EMV Capital PLC
23 December 2025
Β 

For release on Reach: 07.00, 23 December 2025

Β 

EMV Capital plc

(EMVC or Group)

Sofant Technologies: Fundraising

EMV Capital plc (AIM: EMVC), the deep tech and life sciences VC investment group, is pleased to announce that its portfolio company, Sofant Technologies Ltd (Sofant), the Edinburgh-based developer of low-power RF MEMS beamforming solutions for satellite communications, has successfully closed a c.Β£6.25 million equity fundraising (Fundraising). A business update on Sofant also follows.

Fundraising

This is a seminal funding round for Sofant, as the company transitions from multi-year R&D into a commercial launch and production.

The Fundraising was led and syndicated by EMV Capital Partners Limited (EMVCP), the Group's wholly owned venture capital and corporate finance firm. EMVCP played a central role in structuring the round, anchoring it with c.Β£0.75 million of new equity investment, managing loan conversions and aligning all major stakeholders. The round includes significant participation by Scottish Enterprise, the National Security Strategic Investment Fund and other investors. The Fundraising comprises of c.Β£1.1 million of new equity investment together with the conversion of approximately Β£4.7 million of existing loans and accrued interest under convertible loan agreements and approximately Β£430,000 of advance subscriptions. As part of the transaction, a portion of fees owed to EMVCP were converted into equity, further increasing the Group's direct stake.

Proceeds from the Fundraising will support the scaling of Sofant's operations, final qualification of its first commercial products, and preparation for early customer deployments in satellite communications, defence and advanced wireless markets.

Following completion of the Fundraising, the Group's fully diluted equity holding in Sofant is 1.2 per cent, which equates to a post-investment fair value of c.Β£0.6 million. This represents a c.9.3 per cent. increase compared to the fair value amount of Β£0.5 million at 30 June 2025.

In addition, following the introduction of investors to Sofant by EMVCP, the Group's third party assets under management with Sofant will represent 27.0 per cent. of the fully diluted share capital, which equates to a post-investment fair value of c.Β£13.0 million. This represents a c.10.5 per cent. increase compared to the fair value amount of Β£11.8 million at 30 June 2025.

The above percentage holdings are based on fully diluted share capital excluding convertible loan arrangements.

Business update

The Fundraising follows a period of strong technical and commercial momentum for Sofant. In October 2025, the company achieved a major industry breakthrough by successfully demonstrating the world's first fully functioning Ka-band transmit array using its proprietary RF MEMS beamforming IC. This milestone showcased Sofant's ability to achieve the integration of its proprietary technology into a complete transmit array, significantly reducing power consumption, size and thermal demands compared with traditional semiconductor-based systems.

Supported by programmes with the European Space Agency and UK Space Agency, Sofant has advanced the development of its next-generation satellite communication terminal, designed to provide users with high-speed, low-latency satellite connectivity. The technology eliminates the need for complex cooling systems which is a key barrier to scaling modern SatCom and defence platforms.

To support the transition to a scale-up company, Sofant recently appointed Will Whitehorn OBE as Chair, who brings extensive experience in aerospace, satellite communications and commercial scaling. His appointment reflects the company's shift toward international expansion.

David Wither, CEO of Sofant Technologies, commented:

"We are pleased to have secured this significant investment from our existing shareholder base, and to welcome NSSIF as a new strategic shareholder. This support is a testament to the disruptive potential of Sofant's technology and the remarkable progress our team has made in recent months. With this additional capital, we are positioned to accelerate our commercial deployment and redefine what is possible in wireless communications.

"EMVC has supported Sofant through several phases of development, and we would like to thank them for leading this round and for their continued support and guidance, along with our wider shareholder base."

Dr Ilian Iliev, CEO of EMV Capital and Sofant Investor Director, added:

"EMV Capital's anchoring of this pivotal funding round reflects our continued confidence in Sofant's breakthrough low-power RF MEMS technology, which we believe represents a step-change in the architecture of next-generation wireless systems, with the potential to reshape products across defence, aerospace, satellite communications and high-performance enterprise markets.

"This investment fits closely with our investment thesis of providing decisive hands-on support at key value inflection points of our portfolio companies, and to help attract strategic finance.

"We look forward to working closely with the Sofant team as they scale into global markets and unlock the significant value we believe this technology can create."

Β 

-Ends-

Β 

For more information, please contact:

EMV Capital plc

via Rosewood

Ilian Iliev, CEO

Β 

Β 

Β 

Panmure Liberum (UK) Limited (NOMAD and Broker)

+44 (0)20 7886 2500

Emma Earl / Will Goode / Freddy Crossley / Mark Rogers (Corporate Finance)

Β 

Rupert Dearden (Corporate Broking)

Β 

Β 

Β 

Rosewood (Financial PR)

+44 (0)20 7653 8702

John West / Llewellyn Angus / Lily Pearce

Β 

Β 

About EMV Capital plc (EMVC)

EMV Capital plc, is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies.

With a strategic focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future; EMV Capital invests in, manages and strengthens early-stage IP-rich companies.

EMV Capital holds both direct equity stakes and carried interest in its portfolio companies, creating an evergreen structure that supports extensive growth and value creation. EMV Capital's investment thesis is realised through these capital sources:

Β· capital-efficient investments through Group balance sheet;

Β· fund management of the Evergreen EIS and Martlet Capital Funds;

Β· syndicated investments leveraging its network of third-party investors.

EMV Capital's approach is characterised by its proactive management style, aiming to advance portfolio companies to critical value inflection points by actively engaging with them. Companies are supported through Board representation and the use of its Value Creation Services practice.

Headquartered in London, with a Cambridge presence and strong international links, EMV Capital is quoted on the AIM market of the London Stock Exchange.

For more information, visit www.emvcapital.com

About Sofant Technologies

Sofant Technologies is a cutting-edge radio technology company based in Edinburgh, Scotland. Leveraging proprietary RF MEMS technology, Sofant develops ultra-low-power, low-cost platforms that solve critical power and heat challenges in satellite communications and 5G/6G antenna systems. Operating under a fabless semiconductor model, Sofant uses established high-volume, low-cost production methods to deliver game-changing performance at competitive prices.

The company is supported by leading investors including Scottish Enterprise, EMV Capital, Kelvin Capital, Caladan Capital, NSSIF, the UK Space Agency, and the European Space Agency.

For more information, visit www.sofant.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
NRAKZMZZLZGGKZM
12
Date   Source Headline
22nd May 202612:38 pmRNSPosting of Annual Report and Notice of AGM
21st May 20267:00 amRNS-RAMR Bio: Commercial Update
19th May 20267:01 amRNSFinal Results for the year ended 31 December 2025
19th May 20267:00 amRNSPhantom Carried Interest Scheme
14th May 20267:00 amRNSNotice of Final Results
24th Feb 202612:38 pmRNSTR-1
12th Feb 20267:00 amRNS-RPortfolio Update
2nd Feb 20267:00 amRNSTrading and Portfolio Update
8th Jan 20267:00 amRNSPDMR Dealing
23rd Dec 20257:00 amRNS-RSofant Technologies: Fundraising
23rd Dec 20257:00 amRNS-RSofant Technologies: Fundraising
19th Dec 20257:00 amRNSDirector/PDMR Dealing
19th Dec 20257:00 amRNSDirector/PDMR Dealing
10th Dec 20257:00 amRNS-RWanda Health: Fundraising and Business Update
8th Dec 20257:00 amRNSShare Issue, PDMR Dealings & Total Voting Rights
4th Dec 20257:00 amRNSTR-1
24th Nov 20257:00 amRNSExpansion of Senior Finance Leadership Team
20th Nov 20257:00 amRNS-RPortfolio Update
30th Sep 20257:00 amRNSInterim Results and Investor Presentation
22nd Sep 20257:00 amRNSAsset Purchase Agreement with Destiny Pharma
18th Sep 20257:00 amRNSNotice of Interim Results
30th Jun 202512:22 pmRNSResult of AGM
30th Jun 20257:00 amRNSOffice move and Related Party Transaction
27th Jun 20257:00 amRNSQ-Bot Limited Fundraising
10th Jun 20251:28 pmRNSTR-1
6th Jun 20253:12 pmRNSNotice of AGM and Annual Report & Accounts
4th Jun 20252:34 pmRNSDirector/PDMR Shareholding
4th Jun 20257:00 amRNSPreliminary results for the year ended 31 Dec 2024
14th May 20254:02 pmRNSPDS: Q1 Results and Clinical and Corporate Update
9th May 202510:30 amRNSTR-1
27th Mar 20254:46 pmRNSPDS: Q4 Results and Clinical Programs Update
7th Mar 20254:26 pmRNSPDS: VERSATILE-003 Phase 3 Clinical Trial
27th Feb 20254:30 pmRNSPDS: up to $22mn Registered Direct Offering
5th Feb 20253:24 pmRNSPDS Biotech reaffirms guidance for clinical trial
3rd Feb 20257:00 amRNSProAxsis: Status Update and Proposed Fundraise
6th Jan 20254:42 pmRNSTR-1
31st Dec 20247:05 amRNSGrant of Share Options
31st Dec 20247:00 amRNSQ-Bot Fundraising
12th Dec 20244:49 pmRNSTR-1
9th Dec 20247:00 amRNSWanda Health Fundraising
5th Dec 20247:00 amRNSClose of Fundraising and Result of Retail Offer
3rd Dec 20241:24 pmRNSResult of Subscription
3rd Dec 20247:05 amRNSWRAP Retail Offer
3rd Dec 20247:00 amRNSProposed Subscription and Retail Offer; Update
14th Nov 20243:59 pmRNSReplacement RNS: PDS: Update, 3rd Quarter Results
14th Nov 20243:23 pmRNSPDS: Clinical Programs Update, 3rd Quarter Results
8th Oct 20247:00 amRNSDirector/PDMR Shareholding
3rd Oct 20247:00 amRNSDirector/PDMR Shareholding
2nd Oct 20244:38 pmRNSPDS: 36-Month Overall Survival Rate announcement
30th Sep 20247:00 amRNSInterim Results
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.